Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Mar 2023
Zuranolon has been evaluated as a fast-acting, once-daily, oral treatment for 14 days in adults with MDD and PPD. This drug is a positive allosteric modulator of the oral neuroactive steroid GABA-A receptor.
Read Full NewsAripiprazole is associated with a lower risk for hyponatremia compared with olanzapine in patients treated with second-generation antipsychotics, a new cohort study shows.
Researchers evaluate changes in post-transplantation outcomes among patients with relapsed or refractory Hodgkin lymphoma from 2010 to 2022.
In a recent KFF survey, 43% of US adults said they had skipped their medication in the past year because of cost.
1.
Scientists Employ Technology to Identify Plagiarism and Forgeries in Published Studies.
2.
GuCS: Genitourinary Cancers Symposium
3.
Obesity-associated cancers tripled nationwide over past two decades
4.
A new mechanism of radioresistance formation demonstrated in lung adenocarcinoma
5.
EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk.
1.
Everything You Need to Know About RDW-CV: A Comprehensive Guide
2.
Unlocking the Mystery of Methaemoglobinaemia: A New Hope for Treatment
3.
How to Manage Dic with the Right Treatment Approach
4.
Radioligand Therapy Advances: PSMA, Neuroendocrine, and Solid Tumor Clinical Insights
5.
Exploring the Mysteries of Myxoma: A New Frontier in Medical Research
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI
2.
Comprehensive Update on Hematology
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Learning About Different Treatment Approaches For Acute Lymphoblastic Leukemia
5.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge